{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:18Z","timestamp":1786982838757,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008386","name":"Marmara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and acromegaly is unclear due to the complex metabolic effects of growth hormone (GH). GH stimulates gluconeogenesis, glycogenolysis, and lipolysis, increasing free fatty acids, a risk factor for MASLD, but may also protect against hepatic fat accumulation. In this study, we aimed to evaluate the impact of acromegaly and GH levels on liver steatosis and fibrosis using non-invasive FibroScan imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 58 patients with acromegaly, 61 age- and sex-matched metabolically comparable controls, and 82 healthy controls. Hepatic steatosis and fibrosis were assessed via controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) by vibration-controlled transient elastography. Moderate to severe steatosis was defined as CAP\u2009&gt;\u2009260 dB\/m, and significant fibrosis as LSM\u2009\u2265\u20098.0\u00a0kPa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both acromegaly patients and metabolically healthy individuals exhibited lower CAP (241.8\u2009\u00b1\u200950.0 and 231.7\u2009\u00b1\u200951.9 dB\/m) and LSM (4.7\u2009\u00b1\u20091.4 and 4.8\u2009\u00b1\u20091.8\u00a0kPa) scores than metabolically matched controls (CAP 281.7\u2009\u00b1\u200961.2 dB\/m; LSM 5.5\u2009\u00b1\u20091.8\u00a0kPa; CAP\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; LSM\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). Moderate-to-severe steatosis was observed in 36.2% of acromegaly patients, 27.7% of healthy individuals, and 68.8% of metabolically matched controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while significant liver fibrosis occurred in 5.2%, 7.3%, and 14.7%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.154). GH levels were lower in acromegaly patients with MASLD (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to those without. CAP correlated negatively with GH and positively with BMI, waist circumference, and triglycerides, whereas LSM correlated positively with age, BMI, and triglycerides.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hepatic steatosis was less frequent in acromegaly than in metabolically comparable individuals, and GH was inversely associated with hepatic steatosis scores, possibly suggesting a protective role of GH independent of metabolic comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-025-02799-8","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:05:02Z","timestamp":1771596302000},"page":"1029-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-8669","authenticated-orcid":false,"given":"Tugce","family":"Apaydin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0042-9256","authenticated-orcid":false,"given":"Haluk Tarik","family":"Kani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6304-5554","authenticated-orcid":false,"given":"Caglayan","family":"Keklikkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-5283","authenticated-orcid":false,"given":"Yusuf","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-6313","authenticated-orcid":false,"given":"Dilek Gogas","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"11","key":"2799_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/jci39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189\u20133202. https:\/\/doi.org\/10.1172\/jci39375","journal-title":"J Clin Invest"},{"issue":"11","key":"2799_CR2","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1210\/jc.2014-2242","volume":"99","author":"Y Winhofer","year":"2014","unstructured":"Winhofer Y, Wolf P, Kr\u0161\u0161\u00e1k M, Wolfsberger S, Tura A, Pacini G, Gessl A, Raber W, Kukurova IJ, Kautzky-Willer A, Knosp E, Trattnig S, Krebs M, Luger A (2014) No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 99(11):4299\u20134306. https:\/\/doi.org\/10.1210\/jc.2014-2242","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2799_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/a:1023321421760","volume":"5","author":"DR Clemmons","year":"2002","unstructured":"Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3):181\u2013183. https:\/\/doi.org\/10.1023\/a:1023321421760","journal-title":"Pituitary"},{"issue":"2","key":"2799_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N M\u00f8ller","year":"2009","unstructured":"M\u00f8ller N, J\u00f8rgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152\u2013177. https:\/\/doi.org\/10.1210\/er.2008-0027","journal-title":"Endocr Rev"},{"issue":"11","key":"2799_CR5","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/jc.2017-01210","volume":"102","author":"MA Bredella","year":"2017","unstructured":"Bredella MA, Schorr M, Dichtel LE, Gerweck AV, Young BJ, Woodmansee WW, Swearingen B, Miller KK (2017) Body composition and ectopic lipid changes with biochemical control of acromegaly. J Clin Endocrinol Metab 102(11):4218\u20134225. https:\/\/doi.org\/10.1210\/jc.2017-01210","journal-title":"J Clin Endocrinol Metab"},{"key":"2799_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.933039","volume":"13","author":"PU Freda","year":"2022","unstructured":"Freda PU (2022) The acromegaly lipodystrophy. Front Endocrinol (Lausanne) 13:933039. https:\/\/doi.org\/10.3389\/fendo.2022.933039","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2799_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41419-019-1670-6","volume":"10","author":"X Luo","year":"2019","unstructured":"Luo X, Jiang X, Li J, Bai Y, Li Z, Wei P, Sun S, Liang Y, Han S, Li X, Zhang B (2019) Insulin-like growth factor-1 attenuates oxidative stress-induced hepatocyte premature senescence in liver fibrogenesis via regulating nuclear p53-progerin interaction. Cell Death Dis 10(6):451. https:\/\/doi.org\/10.1038\/s41419-019-1670-6","journal-title":"Cell Death Dis"},{"key":"2799_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071447","author":"Y Takahashi","year":"2017","unstructured":"Takahashi Y (2017) The role of growth hormone and insulin-like growth factor-I in the liver. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18071447","journal-title":"Int J Mol Sci"},{"key":"2799_CR9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.02.044","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV, Wai-Sun Wong V, Yilmaz Y, Duseja A, Eguchi Y, Castera L, Pessoa MG, Oliveira CP, El-Kassas M, Tsochatzis E, Fan JG, Spearman CW, Tacke F, Castellanos Fernandez MI, Alkhouri N, Schattenberg JM, Romero-G\u00f3mez M, Noureddin M, Allen AM, Ong JP, Roberts SK, Shubrook JH, Burra P, Kohli R, Kautz A, Holleboom AG, Lam B, Isaacs S, Macedo P, Gastaldelli A, Henry L, Ivancovsky-Wajcman D, Nader F, de Avila L, Price JK, Mark HE, Villota-Rivas M, Barber\u00e1 A, Kalligeros M, Gerber LH, Alqahtani SA (2025) Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.044","journal-title":"Gastroenterology"},{"issue":"6","key":"2799_CR10","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","volume":"79","author":"AL Hutchison","year":"2023","unstructured":"Hutchison AL, Tavaglione F, Romeo S, Charlton M (2023) Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J Hepatol 79(6):1524\u20131541. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.030","journal-title":"J Hepatol"},{"key":"2799_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134638","author":"P Fellinger","year":"2020","unstructured":"Fellinger P, Wolf P, Pfleger L, Krumpolec P, Krssak M, Klavins K, Wolfsberger S, Micko A, Carey P, Gurtl B, Vila G, Raber W, Furnsinn C, Scherer T, Trattnig S, Kautzky-Willer A, Krebs M, Winhofer Y (2020) Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.134638","journal-title":"JCI Insight"},{"issue":"8","key":"2799_CR12","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2015-1917","volume":"100","author":"CM Reyes-Vidal","year":"2015","unstructured":"Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC, Gallagher D, Bruce JN, Post KD, Freda PU (2015) Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab 100(8):2946\u20132955. https:\/\/doi.org\/10.1210\/jc.2015-1917","journal-title":"J Clin Endocrinol Metab"},{"key":"2799_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac014","author":"MC Arlien-S\u00f8borg","year":"2023","unstructured":"Arlien-S\u00f8borg MC, Madsen MA, Dal J, Krusenstjerna-Hafstr\u00f8m T, Ringgaard S, Skou N, H\u00f8gild M, J\u00f8rgensen JOL (2023) Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. Eur J Endocrinol. https:\/\/doi.org\/10.1093\/ejendo\/lvac014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2799_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/eje-12-0252","volume":"167","author":"H Nishizawa","year":"2012","unstructured":"Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y, Yano Y, Kitazawa R, Kitazawa S, Koga M, Okimura Y, Chihara K, Takahashi Y (2012) Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 167(1):67\u201374. https:\/\/doi.org\/10.1530\/eje-12-0252","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2799_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(5):1264-1281.e1264. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"issue":"5","key":"2799_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/meg.0000000000001573","volume":"32","author":"F Jafarov","year":"2020","unstructured":"Jafarov F, Kaya E, Bakir A, Eren F, Yilmaz Y (2020) The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. Eur J Gastroenterol Hepatol 32(5):642\u2013649. https:\/\/doi.org\/10.1097\/meg.0000000000001573","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"2799_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14744\/hf.2022.2022.0042","volume":"4","author":"T Eris","year":"2023","unstructured":"Eris T, Hassan M, Hikal Y, Sawah E, Daneshgar F, Teker AG, Ozel F, Luleci NE, Kaya E, Yilmaz Y (2023) Changes in the etiology of chronic liver disease by referral to a fibroscan center: increasing prevalence of the nonalcoholic fatty liver disease. Hepatol Forum 4(1):7\u201313. https:\/\/doi.org\/10.14744\/hf.2022.2022.0042","journal-title":"Hepatol Forum"},{"key":"2799_CR18","doi-asserted-by":"publisher","unstructured":"Katznelson L, Laws ER Jr., Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","DOI":"10.1210\/jc.2014-2700"},{"issue":"1","key":"2799_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, van der Lely AJ, Wass J, Melmed S (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"issue":"3","key":"2799_CR20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hep.25993","volume":"57","author":"J Boursier","year":"2013","unstructured":"Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Cal\u00e8s P (2013) Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology (Baltimore, Md) 57(3):1182\u20131191. https:\/\/doi.org\/10.1002\/hep.25993","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"2799_CR21","first-page":"17654","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Fan Q, Wang T, Wen J, Wang H, Zhang T (2015) Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med 8(10):17654\u201317663","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"2799_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz099","volume":"6","author":"SE Sansom","year":"2019","unstructured":"Sansom SE, Martin J, Adeyemi O, Burke K, Winston C, Markham S, Go B, Huhn G (2019) Steatosis rates by liver biopsy and transient elastography with controlled attenuation parameter in clinical experience of hepatitis C virus (HCV) and human immunodeficiency virus\/HCV coinfection in a large US hepatitis clinic. Open Forum Infect Dis 6(4):ofz099. https:\/\/doi.org\/10.1093\/ofid\/ofz099","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl","key":"2799_CR23","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L (2025) Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 31(Suppl):S32\u2013s50. https:\/\/doi.org\/10.3350\/cmh.2024.0431","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"2799_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.90","volume":"2","author":"A Koutsou-Tassopoulou","year":"2019","unstructured":"Koutsou-Tassopoulou A, Papapostoli-Sklavounou I, Krawczyk M, Friesenhahn-Ochs B, Weber SN, Lammert F, Stokes CS (2019) Hepatic steatosis in patients with acromegaly. Endocrinol Diabetes Metab 2(4):e00090. https:\/\/doi.org\/10.1002\/edm2.90","journal-title":"Endocrinol Diabetes Metab"},{"key":"2799_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5421961","volume":"2018","author":"A Ciresi","year":"2018","unstructured":"Ciresi A, Guarnotta V, Campo D, Giordano C (2018) Hepatic steatosis index in acromegaly: correlation with insulin resistance regardless of the disease control. Int J Endocrinol 2018:5421961. https:\/\/doi.org\/10.1155\/2018\/5421961","journal-title":"Int J Endocrinol"},{"issue":"1","key":"2799_CR26","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1210\/clinem\/dgad490","volume":"109","author":"I Eroglu","year":"2023","unstructured":"Eroglu I, Iremli BG, Idilman IS, Yuce D, Lay I, Akata D, Erbas T (2023) Nonalcoholic fatty liver Disease, liver Fibrosis, and utility of noninvasive scores in patients with acromegaly. J Clin Endocrinol Metab 109(1):e119\u2013e129. https:\/\/doi.org\/10.1210\/clinem\/dgad490","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2799_CR27","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s40618-024-02384-5","volume":"47","author":"M Coskun","year":"2024","unstructured":"Coskun M, Sendur HN, Babayeva A, Cerit MN, Cerit ET, Yalcin MM, Altinova AE, Akturk M, Karakoc MA, Toruner FB (2024) Quantitative ultrasound techniques and biochemical markers to assess liver steatosis and fibrosis in newly diagnosed acromegaly. J Endocrinol Invest 47(11):2823\u20132833. https:\/\/doi.org\/10.1007\/s40618-024-02384-5","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2799_CR28","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad028","volume":"7","author":"AP Kuker","year":"2023","unstructured":"Kuker AP, Shen W, Jin Z, Chen J, Bruce N, Freda PU (2023) Long-term outcome of body composition, ectopic lipid, and insulin resistance changes with surgical treatment of acromegaly. J Endocr Soc 7(5):bvad028. https:\/\/doi.org\/10.1210\/jendso\/bvad028","journal-title":"J Endocr Soc"},{"issue":"10","key":"2799_CR29","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1210\/jc.2009-0438","volume":"94","author":"MA Bredella","year":"2009","unstructured":"Bredella MA, Torriani M, Thomas BJ, Ghomi RH, Brick DJ, Gerweck AV, Miller KK (2009) Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. J Clin Endocrinol Metab 94(10):3995\u20134002. https:\/\/doi.org\/10.1210\/jc.2009-0438","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2799_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ghir.2008.03.003","volume":"18","author":"Z Laron","year":"2008","unstructured":"Laron Z, Ginsberg S, Webb M (2008) Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Horm IGF Res 18(5):434\u2013438. https:\/\/doi.org\/10.1016\/j.ghir.2008.03.003","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"2799_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1053\/j.gastro.2006.12.024","volume":"132","author":"Y Takahashi","year":"2007","unstructured":"Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S, Chihara K (2007) Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 132(3):938\u2013943. https:\/\/doi.org\/10.1053\/j.gastro.2006.12.024","journal-title":"Gastroenterology"},{"issue":"12","key":"2799_CR32","doi-asserted-by":"publisher","first-page":"e1542","DOI":"10.1210\/clinem\/dgad375","volume":"108","author":"LE Dichtel","year":"2023","unstructured":"Dichtel LE, Corey KE, Haines MS, Chicote ML, Lee H, Kimball A, Colling C, Simon TG, Long MT, Husseini J, Bredella MA, Miller KK (2023) Growth hormone administration improves nonalcoholic fatty liver disease in overweight\/obesity: a randomized trial. J Clin Endocrinol Metab 108(12):e1542\u2013e1550. https:\/\/doi.org\/10.1210\/clinem\/dgad375","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2799_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cen.14344","volume":"94","author":"CS Pan","year":"2021","unstructured":"Pan CS, Weiss JJ, Fourman LT, Buckless C, Branch KL, Lee H, Torriani M, Misra M, Stanley TL (2021) Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. Clin Endocrinol 94(2):183\u2013192. https:\/\/doi.org\/10.1111\/cen.14344","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2799_CR34","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1210\/jc.2004-1657","volume":"90","author":"C Franco","year":"2005","unstructured":"Franco C, Brandberg J, L\u00f6nn L, Andersson B, Bengtsson BA, Johannsson G (2005) Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 90(3):1466\u20131474. https:\/\/doi.org\/10.1210\/jc.2004-1657","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2799_CR35","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/s2352-3018(19)30338-8","volume":"6","author":"TL Stanley","year":"2019","unstructured":"Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK (2019) Effects of Tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 6(12):e821\u2013e830. https:\/\/doi.org\/10.1016\/s2352-3018(19)30338-8","journal-title":"Lancet HIV"},{"issue":"4","key":"2799_CR36","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/jc.2011-2681","volume":"97","author":"M Madsen","year":"2012","unstructured":"Madsen M, Krusenstjerna-Hafstrom T, Moller L, Christensen B, Vendelbo MH, Pedersen SB, Frystyk J, Jessen N, Hansen TK, Stodkilde-Jorgensen H, Flyvbjerg A, Jorgensen JO (2012) Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. J Clin Endocrinol Metab 97(4):1227\u20131235. https:\/\/doi.org\/10.1210\/jc.2011-2681","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2799_CR37","doi-asserted-by":"publisher","first-page":"15273","DOI":"10.1038\/s41598-018-33419-6","volume":"8","author":"R Fan","year":"2018","unstructured":"Fan R, Wang J, Du J (2018) Association between body mass index and fatty liver risk: a dose-response analysis. Sci Rep 8(1):15273. https:\/\/doi.org\/10.1038\/s41598-018-33419-6","journal-title":"Sci Rep"},{"key":"2799_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/hmer.S45234","volume":"5","author":"E Durango","year":"2013","unstructured":"Durango E, Dietrich C, Seitz HK, Kunz CU, Pomier-Layrargues GT, Duarte-Rojo A, Beaton M, Elkhashab M, Myers RP, Mueller S (2013) Direct comparison of the fibroscan XL and M probes for assessment of liver fibrosis in obese and nonobese patients. Hepatic Medicine: Evid Res 5:43\u201352. https:\/\/doi.org\/10.2147\/hmer.S45234","journal-title":"Hepatic Medicine: Evid Res"},{"key":"2799_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1362396","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Li H, Wang X, Shi R, Hu J, Zeng X, Luo H, Yang P, Luo H, Cao Y, Cai X, Chen S, Wang D (2024) Association between triglyceride to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease and liver fibrosis in American adults: an observational study from the National Health and Nutrition Examination Survey 2017\u20132020. Front Endocrinol (Lausanne) 15:1362396. https:\/\/doi.org\/10.3389\/fendo.2024.1362396","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02799-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02799-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02799-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:11:36Z","timestamp":1776247896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02799-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02799-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}